People's Health Movement PHM - re-establish health and equitable development as top priorities with comprehensive primary health care


home page contact us     

About PHM News Room Events PHM Worldwide Campaigns Publications

Charters Voices PHA 2000 Links Get Involved Spanish
 The Agreement on the Application of Sanitary and Phytosanitary Measures (SPS)

Last Update:  March 14, 2005 

 
 
Quick Feedback
Has this information been
useful? Yes    No
Name
Email
Keep me informed
Thank you

 
   Issue Papers
Africa Immunization
Environmental Links
Critical Issues
Exporting Curruption
Kerala Campaign
Healthcare Sevices
Mental Health
Time Bank Network
R & D
Principle Actors
Food Security
Holistic Health
Health-Development
Healthcare Reforms
Impact on Health
Unequal Relations
Globalization-Health
Globalization
Decentralization
Pre PHA 2000

 

The Agreement on the Application of Sanitary and Phytosanitary Measures (SPS) - Globalisation and the Impact on Health - A Third World View - Issue Papers

Globalisation and the Impact on Health
A Third World View - The Agreement on the Application of Sanitary and Phytosanitary Measures (SPS)

 
This complete document inThis document in pdf formatpdf format 458 kb
 
Evelyne Hong

August 2000 
 

References
Conclusion
Socio Economic Causes of Ill Health
The Asian Financial Crisis
The US-UN Sanctions on Iraq
The Culture of Violence
The Globalisation of Culture
The Agreement on Agriculture (AOA)
The General Agreement on Trade in Services (GATS)
The Agreement on Trade Related Aspects of Intellectual Property (TRIPs)
The Agreement on Technical Barriers to Trade (TBT)
The Agreement on the Application of Sanitary and Phytosanitary Measures (SPS)
The World Trade Organisation (WTO)
The Role of the World Bank
The Global Assault on Health
Impact of SAPs in the Third World
Structural Adjustment Programmes (SAPs)
The Role of the World Bank in Global Economic Reform
Free Market Rules
Free Market Reform
Post-Colonial Development Strategy
Integration into the Market
The Colonial Enterprise
Introduction

 
 
 
The Agreement on the Application of Sanitary and Phytosanitary Measures (SPS)
 

The SPS Agreement has particular relevance to the trade in foods: it deals with issues related to food safety and animal and plant health laws. The Agreement recognises the rights of governments to protect human, animal or plant life or health based on sound principles and scientific evidence and that the measures are not used as a pretext for erecting technical barriers to protect domestic markets. It should not discriminate between member states with similar or identical conditions prevailing. The Agreement states that members must base their SPS measures on international standards, guidelines and recommendations if they exist.

While the WTO agreements are based on relevant international standards, it is not always defined who or what should be the body which sets the international standards, thus creating opportunities for industry led self regulation.

Though the SPS Agreement explicitly mentions some international benchmarks, there is a danger that commercially driven voluntary standards and codes of conduct which are lower than the standards of international regulatory agencies will be used (Koivusalo:1999) This will have serious implications for health.

The international standards used in WTO disputes and as the basis of international standards in food matters are the Codex Alimentarius (CA). The CA is defined by the Food and Agriculture Organisation (FAO) and the WHO and has acquired new importance with trade liberalisation under the WTO regime. However there are concerns that the CA has been dominated by commercial interest. Between 1989-91, 96 percent of the non-governmental participants or national delegations represented industry and Nestle sent 38 representatives to Codex committee meetings, which is more than most countries. In the committee on pesticide residue levels, 33 percent of participants came from agro chemical and food corporations. This raises questions concerning the objectivity and impartiality of the Codex in scientific assessment (Koivusalo: 1999).

For example in the 1990s Codex allowed residues of DDT on numerous foods in sharp contrast to the US ban on DDT imposed in the 1970s (Goldman & Wagner 1999). Forty two percent of the Codex standards for pesticides are lower than US EPA & FDA standards and fifty times more DDT may be used on or left in residual amounts on peaches, bananas; and thirty three times more DDT may be applied on brocolli (Goldsmith 1996:90).

In the beef hormone case, the EU challenged the CA standard. The Joint FAO-WHO Expert Committee on Food Additives which is an advisory body to the CA Commission had concluded in 1988 that ‘residues resulting from the use of (these substances) as growth promoters in accordance with good animal husbandry practice are unlikely to pose a hazard to human health’ (WHO 1988). This evaluation had provided the basis for the relevant CA standard. The dispute settlement panel and the AP both found that the EU’s ban was inconsistent with the relevant articles of the SPS Agreement. In other words, that the EU had not conducted appropriate risk assessment or provided scientific evidence to support its ban (Kinnon 1998).

We have seen how the guidelines of other international scientific bodies have been ignored for example in the beef hormone dispute, IARC studies were considered irrelevant. The beef hormone case clearly shows that risk assessment has been defined in highly quantitative and scientific terms measuring specific exposures generated by specific products and the effect on human health or mortality. This excludes low level exposures which are technically impossible to measure and does not allow scope for the application of the Precautionary Principle thus opening up areas for future disputes for instance in the recent dispute with the EU, Canada challenged the EU’s standards for exposure to asbestos which are more stringent. While asbestos is acknowledged as a carcinogen, the carcinogenicity of asbestos at low exposure is very hard to show, even when a known risk exists.

Narrowing the intepretation of risk assessment in such a manner ensures weak and loose regulatory standards (Koivusalo 1999). The fact that the DSB panels comprising individuals with competence in trade laws and policies are given the authority to judge the legitimacy of national regulations such as health in which they have no expertise; in the absence of any transparent or open process and public scrutiny goes against all rules of fairplay and justice. Even worse, the decisions made by the DSB can pose a threat to public health and safety.

Given that the overarching aim of the WTO is to facilitate trade, the guiding principles for food safety measures is towards ‘downward harmonisation’ of health and environmental standards, risks assessment supported by scientific evidence and equivalence. This will pose a major challenge to international standards in health protection currently being developed eg WHO’s International Framework Convention on Tobacco Control; as well as others like the International Code of Marketing of Breastmilk Substitutes (Koivusalo 1999); The Revised Drug Strategy and The Cartegena Protocol on Biosafety.

There are other grey areas which hold the potential for future disputes. These are issues where scientific uncertainty is large or where regulatory measures currently in place are not geared to assessments of specific products, that is, they are not very exact in their assessments of the risks of specific products, but geared more to addressing risky or problematic practices, misuse or abuse. These could cover the following issues based on Koivusalo’s (1999) research and analysis:

  • Implementing precautionary measures in cases where scientific evidence does not exist or is problematic due to minor risks of widespread exposure which has potentially serious long-term implications, e.g.:

  • substances with potential hormonal or carcinogenic impacts; bioaccumulative substances;

  • substances with population-level associations with chronic diseases;

  • substances in relation to which prior knowledge of related substances suggests caution e.g stabile organo-chlorine compounds or hormone derivatives.

  • Regulating new or newly developed products where scientific evidence and risk assessment procedures may remain confidential and protected due to their commercial nature, e.g.:

    • GM foods, bio- and genetechnology products;

    • newly developed pharmaceuticals;

    • pesticides and other chemical products;

    • food additives.

  • Implementing regulatory measures to deal with inappropriate measures in production methods which have broader health implications than simply those related to consumption or use of the end product, e.g.:

    • GM foods and ‘terminator seeds’ which may give only one crop;

    • Use of antibiotics and hormones in cattle breeding.

  • Implementing regulatory measures where the product as such may not be dangerous to health but where regulatory measures may be the least costly and easiest way of avoiding inappropiate use in the local context, e.g.:

    • breast milk substitute marketing and marketing products for children;

    • any products for which health impacts are related to inappropriate use e.g. medicines.
       

Next >>

Quick Feedback: Has this information been useful?

 

 

 
 Back Home Up Next [include/copyright.htm]